Are targeted therapies now a thing of the past in the immunotherapy era?
With the sheer breadth and depth of immuno-oncology data being presented at even the American Association for Cancer Research (AACR), several readers were prompted to write in and ask:
“Is this the end of the road for TKI therapies? Should we even bother to continue working on these agents?”
Good question.
There was actually quite a bit of interesting data on regular novel targeted therapy to discuss, although I do concede that much of the mass media news focusing on the immuno-oncology tsunami in Philadelphia effectively drowned out targeted therapies and the results coming out in that space.
To maintain the balance between novel targeted agents and immunotherapy, here’s a review of some of the interesting new developments that I came across at AACR, from both the poster halls, as well as some of the thought leaders in this space.
When you stack up the emerging evidence in several tumour subsets, there are quite a few tasty morsels that are worthy of further discussion!
I’d like to take this opportunity to extend a warm welcome to all the new subscribers who took advantage of the AACR Special Offer to continue their education and learning about the exciting new developments in cancer research. Thank you for joining our conference coverage service, we really appreciate it.
To learn more about our latest insights, subscribers can log-in or you can purchase access to BSB Premium Content.
This content is restricted to subscribers
2 Responses to “Are targeted therapies now a thing of the past in the immunotherapy era?”
Thanks Sally, nice post. Do you know if it would be possible to pick up MET amplification by ctDNA? I seem to remember Ross Camidge saying at ASCO14 that it can only be detected by FISH.
As far as I can work out, Dr Camidge is indeed correct. There are some groups working on this I believe, but commercially it’s still FISH or IHC for now.
Comments are closed.